Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

XOMA

XOMA (XOMA)

XOMA Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XOMA
DateTimeSourceHeadlineSymbolCompany
05/09/20246:30AMGlobeNewswire Inc.XOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAXOMA Corporation
04/30/20246:30AMGlobeNewswire Inc.XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%NASDAQ:XOMAXOMA Corporation
04/25/20246:30AMGlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Corporation
04/24/20248:00AMPR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:XOMAXOMA Corporation
04/03/20248:00AMGlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAXOMA Corporation
03/21/20246:30AMGlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Corporation
03/19/20243:05PMGlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAXOMA Corporation
03/08/20246:30AMGlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Corporation
02/28/20246:30AMGlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAXOMA Corporation
02/16/20247:00AMGlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAXOMA Corporation
01/18/20247:30AMGlobeNewswire Inc.XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionNASDAQ:XOMAXOMA Corporation
01/11/20243:50PMDow Jones NewsXoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolNASDAQ:XOMAXOMA Corporation
01/11/20243:05PMGlobeNewswire Inc.FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxNASDAQ:XOMAXOMA Corporation
01/08/20246:30AMGlobeNewswire Inc.XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsNASDAQ:XOMAXOMA Corporation
01/02/20246:30AMGlobeNewswire Inc.XOMA Announces Stock Repurchase Program of up to $50 MillionNASDAQ:XOMAXOMA Corporation
12/20/20236:30AMGlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Corporation
12/19/20236:30AMGlobeNewswire Inc.XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesNASDAQ:XOMAXOMA Corporation
11/07/20236:30AMGlobeNewswire Inc.XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Corporation
10/31/20236:30AMGlobeNewswire Inc.XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Corporation
09/25/20236:30AMGlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Corporation
09/06/20236:30AMGlobeNewswire Inc.XOMA to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:XOMAXOMA Corporation
08/08/20236:30AMGlobeNewswire Inc.XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyNASDAQ:XOMAXOMA Corporation
06/23/20235:14PMGlobeNewswire Inc.XOMA Added to the Russell 2000® and Russell 3000® IndexesNASDAQ:XOMAXOMA Corporation
06/22/20236:30AMGlobeNewswire Inc.XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology AssetNASDAQ:XOMAXOMA Corporation
06/20/20236:30AMGlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Corporation
05/25/20233:34PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAXOMA Corporation
05/22/20233:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAXOMA Corporation
05/22/20233:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAXOMA Corporation
05/19/20234:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAXOMA Corporation
05/19/20233:32PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAXOMA Corporation
 Showing the most relevant articles for your search:NASDAQ:XOMA